Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
MicroPort makes medical devices — stents, joint replacements, heart pacemakers, and surgical robots — that doctors implant or use inside patients' bodies to fix serious health problems.
MicroPort is a Chinese medical-device maker. Its core business is building the small, high-tech hardware that goes inside a human body: tiny mesh tubes called stents that hold open blocked heart arteries, artificial joints for hips and knees, pacemakers that keep a heart beating in rhythm, and tools for treating blood vessels in the brain. It also builds surgical robots that let doctors operate with steadier, more precise hands. Hospitals and surgeons are the customers — they buy the implants and instruments, and patients ultimately benefit from them.
The company started in 1998 with a single product: a coronary stent made in China, at a time when that market was dominated by foreign giants. That first stent was a big deal because it gave Chinese hospitals a domestic option that cost less than imported brands. From there MicroPort expanded by buying its way into new body parts. It picked up a major orthopedic business (artificial joints) and, later, a cardiac rhythm business (pacemakers and defibrillators), turning itself from a one-product stent maker into a group that sells across several medical specialties. Today it sells worldwide, not just in China. The business is expensive to run. Medical devices must pass rigorous regulatory approval in each country — a slow, costly process — and then compete on clinical evidence and surgeon relationships. MicroPort spends heavily on research and development and on building sales teams that can walk surgeons through new products. That spending has kept the company thin on profit even as revenue grew. It competes against much larger global players such as Medtronic, Abbott Laboratories, and Boston Scientific, plus a growing pack of Chinese rivals that have pushed stent prices down hard through government bulk-purchasing programs.
That price pressure is the key thing to understand about MicroPort. China's centralized procurement drive slashed what hospitals pay for stents, squeezing margins across the industry. The company's answer has been to climb toward more complex, higher-value devices — neurovascular tools, surgical robots, and heart-rhythm products — where competition is thinner and prices hold up better. It is essentially a bet that smarter, more specialized hardware can outrun the commodity squeeze on its original bread-and-butter products. Whether that bet pays off depends on winning regulatory approvals and convincing surgeons that its newer devices are worth choosing.
Saved answer · last researched 16 Nov 2026